FDA Announces Label Change For Raptiva

Jamie G. Goldstein

Attorney
(866) 735-1102 Ext 626

0 CommentsPrint ArticleSubscribe

The FDA has announced the drug Raptiva will undergo a label change that will include a boxed warning, the FDA's strongest warning. Raptiva is a psoriasis drug that has recently been linked to serious infections and death.

The FDA is warning consumers that Raptiva may cause a suppression of the immune system. This suppression of the immune system is created to reduce psoriasis flare ups. The suppression, however, may also result in the increased likelihood of developing serious infections, which may include cancer.

If you are considering using Raptiva, make certain you speak with your doctor so you understand the risks and benefits of taking Raptiva. Make certain you are fully informed of the dangers associated with Raptiva before taking it.

If you or a family member has taken Raptiva in the past and has suffered a serious infection or death, contact an attorney. The infection may have been a result of the use of Raptiva and you may be able to recover for the injuries you suffered.